The potential developmental toxicity of fleroxacin was studied (Phase I) and its pharmacokinetics was compared to ciprofloxacin, temafloxacin, and norfloxacin (Phase H) in the cynomolgus macaque (Macacafascicularis). Phase I studies involved oral administration of fleroxacin (35 and 70 mg/kg-day) during Gestational Days (GD) 20-34 or 35-49 (N = 10/group); controls received vehicle only. Increased maternal toxicity (weight loss, anorexia, emesis) and embryolethality (4/10, 40%; GD 20-34) were observed at 70 mg/kg-day. Urinary excretion of estrogen conjugates was reduced for females with nonviable pregnancies during both treatment periods (GD 20-34 and 35-49), although steroid hormone levels in serum remained unchanged during treatment; no malformations or growth retardation were observed at gross examination. For Phase 11 studies, the pharmacokinetics of fleroxacin (70 mg/kg), ciprofloxacin (100 mg/kg), temafloxacin (100 mg/kg), and norfloxacin (150 mg/kg) were studied during a 3-day oral treatment regimen in the nonpregnant (N = 12; 3/quinolone) and pregnant (N = 3; fleroxacin only) macaque. Serial blood samples were collected on the first and third days of treatment in all animals; for pregnant females, the conceptus was removed on GD 31 for analysis of fleroxacin levels. Marked differences between the quinolones were noted in the AUC" " for nonpregnant females. Based on AUCO24 " on the first day of treatment, the rank order was fleroxacin > temafloxacin > ciprofloxacin > norfloxacin. On the third day of treatment, the rank order for exposure was temafloxacin > fleroxacin > ciprofloxacin > norfloxacin. Overall, results indicated (1) no marked differences in pharmacokinetic parameters in pregnant versus nonpregnant females, (2) fleroxacin levels in embryonic tissues were similar to maternal plasma levels, and (3) there was a correlation between exposure and embryolethal doses for all fluoroquinolones which resulted in embryolethality except norfloxacin.
The potential developmental toxicity of fleroxacin was studied (Phase I) and its pharmacokinetics was compared to ciprofloxacin, temafloxacin, and norfloxacin (Phase H) in the cynomolgus macaque (Macacafascicularis) . Phase I studies involved oral administration of fleroxacin (35 and 70 mg/kg-day) during Gestational Days (GD) 20-34 or 35-49 (N = 10/group); controls received vehicle only. Increased maternal toxicity (weight loss, anorexia, emesis) and embryolethality (4/10, 40%; GD 20-34) were observed at 70 mg/kg-day. Urinary excretion of estrogen conjugates was reduced for females with nonviable pregnancies during both treatment periods , although steroid hormone levels in serum remained unchanged during treatment; no malformations or growth retardation were observed at gross examination. For Phase 11 studies, the pharmacokinetics of fleroxacin (70 mg/kg), ciprofloxacin (100 mg/kg), temafloxacin (100 mg/kg), and norfloxacin (150 mg/kg) were studied during a 3-day oral treatment regimen in the nonpregnant (N = 12; 3/quinolone) and pregnant (N = 3; fleroxacin only) macaque. Serial blood samples were collected on the first and third days of treatment in all animals; for pregnant females, the conceptus was removed on GD 31 for analysis of fleroxacin levels. Marked differences between the quinolones were noted in the AUC" " for nonpregnant females. Based on AUCO24 " on the first day of treatment, the rank order was fleroxacin > temafloxacin > ciprofloxacin > norfloxacin. On the third day of treatment, the rank order for exposure was temafloxacin > fleroxacin > ciprofloxacin > norfloxacin. Overall, results indicated (1) no marked differences in pharmacokinetic parameters in pregnant versus nonpregnant females, (2) fleroxacin levels in embryonic tissues were similar to maternal plasma levels, and (3) there was a correlation between exposure and embryolethal doses for all fluoroquinolones which resulted in embryolethality except norfloxacin. © 1993 Academic Press, Inc.
Derivatives of nalidixic acid, the newly synthesized quinolones, have expanded the antimicrobial spectrum when compared to the parent compound. In addition to being highly active against a wide variety of aerobic organisms including several nosocomial multiresistant pathogens (Paton and Reeves, 1988) , the fluoroquinolones are highly effective in the treatment of urinary tract infections (UTI), a common medical complication of pregnancy (Malinverni and Glauser, 1988; Scully, 1990) . The effectiveness of the fluoroquinolones is due to their ability to inhibit supercoiling activity of the DNA gyrase enzyme (Chu and Fernandes, 1989; Paton and Reeves, 1988) . All the quinolones are bactericidal and possess in vivo activity against gramnegative bacteria; only some demonstrate marked in vivo activity against gram-positive organisms as well.
The choice of treatment for pregnant women with UTI remains controversial due to the limited information available regarding the use of antimicrobials during pregnancy. Due to the efficacy of the fluoroquinolones, they are frequently considered the first choice for therapy. Based on these considerations, efforts to study the potential for developmental toxicity/teratogenicity with the nonhuman primate as a model for the human have been undertaken. Compounds which have been studied in gravid female macaques include norfloxacin (Cukierski et al., 1989 (Cukierski et al., , 1992 , ciprofloxacin (Schluter, 1989) , and temafloxacin (Tarantal et al., 1990) . The results of these studies in combination have allowed some conclusions to be drawn regarding the overall potential for developmental toxicity of these agents in the gravid macaque. First, exposure of the conceptus to the quinolones does not appear to result in growth retardation or gross malformations. These studies have focused on treatment during organogenesis (Gestational Day (GD) 20-50); no gross abnormalities were detected in embryos or fetuses exposed to the above compounds. Second, a significant finding which has been observed with three of four agents evaluated (fleroxacin, norfloxacin, temafloxacin) has been an increase in embryolethality after exposure to the higher doses (70-300 mg/kg-day). Prenatal exposure to temafloxacin (orally during GD 20-50) resulted in a significant increase in prenatal loss at 100 mg/kg-day (5/10-50%; embryonic death detected GD 25-50) (Tarantal et al., 1990) , studies with norfloxacin (oral treatment during GD 21-50) resulted in a 30% (3/10) incidence of embryolethality at 150 mg/kg-day and a 69% (11/16) loss at 200/300 mg/kg-day (Cukierski et al., 1989) , whereas ciprofloxacin did not result in embryolethality at doses up to 100 mg/kgday. All studies incorporated serum hormone analyses (progesterone (P), 170-estradiol (E2), chorionic gonadotropin (CG)) in an effort to determine whether drug exposure affected placental function. Only studies with norfloxacin suggested an alteration of trophoblast function, namely a reduction in P production (Cukierski et al., 1989 (Cukierski et al., , 1992 .
Based on these results and those obtained from the fleroxacin study described herein, a comparison of the pharmacokinetics of the four fluoroquinolones (fleroxacin, ciprofloxacin, temafloxacin, norfloxacin) in nongravid monkeys was proposed as an initial step toward investigating the mechanism(s) responsible for the high rate of embryonic loss. An additional study with fleroxacin in gravid animals was incorporated, in order to focus on the potential differences in drug disposition during pregnancy (Mattison et al., 1991) . The overall goal of these pharmacokinetic studies was to attempt to correlate systemic levels achieved in prior developmental toxicity studies with adverse pregnancy outcome.
MATERIALS AND METHODS
Adult female cynomolgus macaques (Macaca fascicularis) were used for all phases of the studies described below. Animals were housed and maintained as previously described (Tarantal et at, 1990) . The California Regional Primate Research Center (CRPRC) is fully accredited by AAALAC with all research protocols and procedures related to these studies approved through the University of California at Davis Animal Use and Care Committee, the campus veterinarian, and the CRPRC.
Daily visual examinations were performed in order to detect the first day of menstrual bleeding which was considered Day 1 of the cycle. Females were bred midcycle to proven fertile males 1-8 hr/day every other day over a 3-day period (2 days mating). A successful mating was confirmed by the presence of sperm in a vaginal smear after removing the male. GD 0 was assigned to the last day of the mating period. Pregnancy was confirmed by assay of CG and/or ultrasound (Tarantal and Hendrickx, 1988a) . For Phase 11 (pharmacokinetics) nonpregnant animals were chosen in groups with comparable cyclicity in order to standardize treatments in relation to the stage of the menstrual cycle (luteal phase).
Animals were weighed prior to the initiation of treatment, biweekly (Phase 1) or weekly (Phase II) during the treatment period and then monthly thereafter. Physical signs were observed twice daily for evidence of toxicity and vaginal hemorrhage-once in the morning then within 2 hr following drug administration. All maternal blood samples were collected from a peripheral vessel from hand-restrained (unanesthetized) females (Phase I) or chair restrained animals (Phase II) at the same time each day; the serum was frozen at -50°C until assay.
All fluoroquinolones were provided by F. Hoffmann-LaRoche, Basel, Switzerland (see Fig. t ).
Phase 1: Developmental Toxicity of Fleroxacin

Animals
A total of 50 pregnant females were assigned to successive treatment groups (0, 35, and 70 mg/kg-day) and treatment periods (GD 20-34 or 35-49) on a rotational basis beginning with the high dose group (70 mg/kg) and the early treatment period (GD 20-34) to achieve 10 animals in each of the drug-treated groups and 5 vehicle controls (N = 25). Assignment to the GD 35-49 treatment period was then initiated, beginning with the high dose group (70 mg/kg) following a similar rotation as noted above (N = 25).
Drug Preparation
Fleroxacin was prepared fresh daily by homogenizing the appropriate amount of compound into suspension with the vehicle (0.3% carboxymethylcellulose/distilled water) to achieve a dosing volume of 5 ml/kg based on each animals body weight, and administered via nasogastric intubation each day . The dosing suspension was prepared in excess to allow for loss during preparation and resuspended prior to dosing to ensure homogeneity at the time of administration. Six times during the treatment period a sample of each dosing suspension was collected from the top, middle, and bottom of the preparation container for analysis of concentration and uniformity. Samples were collected, frozen, and stored at ,-50°C until analysis.
Experimental Design
All pregnancies were monitored sonographically during gestation in order to verify embryonic growth and to confirm viability as evidenced by the presence of cardiac motion (Tarantal and Hendrickx, 1988b) . Examinations were performed on GD 24, 28, 32, and 36 ± 2 for the GD 20-34 treatment period and GD 33, 40, 45, and 50 ± 2 for the GD 35-49 treatment period. Animals were hand-held by animal handlers for the examinations. When a nonviable embryo was detected, a hysterotomy was performed and the conceptus was removed for evaluation.
Blood samples were collected once pretreatment, five times during the treatment period, and once post-treatment for analysis of P (Abraham et 1971) for all animals on study. Analyses of CG were included for animals treated during GD 20-34 since CG is only detectable in macaques during this time period. Approximately 2 ml of whole blood was collected and allowed to clot at room temperature. Serum was harvested, frozen, and stored at ----50°C until assay. The interassay coefficient of variation for P was 19.9%; assay sensitivity was 0.0156 ng/ml. The CG assay measures relative concentrations of macaque CG (Tarantal et al., 1993) ; the interassay coefficient of variation was 7.4% and the assay sensitivity was 30 ng/ml.
Twenty-four-hour urine samples were collected from cage pans from all animals pretreatment, daily throughout treatment, and for 3 days posttreatment for analyses of urinary estrone conjugates (E,C) (Monfort et al., 1986) . Approximately 4 ml of urine was collected, frozen, and stored at -20°C until analysis (indexed by creatinine). The interassay coefficient of variation for E,C was 12.6%; the assay sensitivity was 0.039 ng/tube. Hysterotomies were performed on GD 100 ± 2 and fetuses were subjected to a standard teratologic examination which included a gross examination; external measurements including body weight; crown rump, crown-hip, femur, and foot lengths; biparietal and occipitofrontal diameters; head circumference; anogenital distance; a placental examination; visceral examination which included evaluation of the gross appearance and weight of the brain, thymus, spleen, liver, adrenals, and kidneys; and a skeletal examination of Alizarin red S-stained carcasses.
Statistical Analyses
Statistical significance of abortion rates was determined by Fisher's exact test (95% confidence interval), and group differences were assessed with repeated measures analysis (analysis of variance (ANOVA)) and the Student t test where appropriate. 
Phase II: Comparative Pharmacokinetics
Animals
Fifteen females were selected for these studies; 12 nonpregnant and 3 pregnant animals all with previous chair-restraint training (Anderson and Houghton, 1983) .
Drug Preparation
Four fluoroquinolones were studied (fleroxacin, ciprofloxacin, temafloxacin, norfloxacin) (Fig. 1) . Purity of the fluoroquinolones was 99.7, 98.5, 99.9, and 99.4%, respectively. All of the dosage forms were prepared fresh daily by homogenizing the appropriate amount of each individual fluoroquinolone into suspension with the vehicle (0.3% carboxymethylcellulose) in distilled water to achieve appropriate dosing concentrations, as noted under Experimental Design below. Efforts were made to maintain standardized conditions in order to avoid any potential deviations of plasma levels by difference in particle size and/or inhomogeneity of the suspensions. A dosing volume of 5 ml/kg was calculated based on each animal's body weight which was obtained 3 days prior to the initiation of treatment. The dosing suspension was prepared in excess to allow for loss during preparation and resuspended prior to administration to ensure homogeneity. Once during the treatment period, a sample of each dosing suspension for each respective quinolone was collected from the bottom, middle, and top of each suspension for analysis of concentration and uniformity. Each quinolone was administered via nasogastric intubation at a dosing concentration as follows: fleroxacin (70 mg/kg-day), ciprofloxacin (100 mg/kg-day), temafloxacin (100 mg/kg-day), and norfloxacin (150 mg/kg-day).
Experimental Design
Nonpregnant animals. Each respective quinolone was administered orally via nasogastric intubation to a total of three animals during Menstrual Cycle Days 19-21. Animals were placed in restraint chairs immediately prior to dosing on Cycle Days 19 (Day 1 of treatment) and 21 (Day 3 of treatment) for collection of serial blood samples as follows: 0 (pretreatment), 1, 2, 3, 5, 7, and 24 hr post-treatment. Animals were removed from the restraint chairs after the 7-hr time point and returned to their cages. Blood samples were collected via arm extension at 24 hr post-treatment. The samples collected (1 ml per time point; collected into potassium oxalate) were centrifuged for 10 min, and the plasma was frozen and stored at ---c.-50°C until analysis.
Pregnant animals. Three pregnant animals were assigned to the fleroxacin study and treated orally via nasogastric intubation on GD 28-30. Embryonic viability was documented sonographically during the study period. Animals were hand-caught by animal handlers for ultrasound evaluations pretreatment (GD 27 ± I) and then daily immediately prior to treatment (Tarantal and Hendrickx, I 988b) . On GD 28 and 30 they were placed in restraint chairs for blood sampling immediately after viability was confirmed. Blood samples were collected on the first (GD 28) and third days of treatment (GD 30) as follows: 0 (pretreatment), 1, 2, 3, 5, and 7 (all while chair-restrained), and then at 24 hr post-treatment (arm extension from cage). Samples were collected, centrifuged, stored, and analyzed as discussed above. The conceptus was removed by hysterotomy on GD 31. The embryo, chorionic fluid, and placenta were dissected and separated for determination of drug concentrations.
Drug Analyses
Dosing formulations were analyzed by HPLC and an assessment of particle size was performed. For determination of particle size, saturated solutions of each test compound were prepared in 0.1% aqueous Tween 80 and filtered through a 0.45-pm filter. After addition of each respective dosing suspension, the particle size was assessed by low-angle forward scattering of light obtained from a Helos instrument (Sympatec Gmbh, D-3346 Remlingen, Germany). Ultrasonification was performed in order to deflocculate aggregates, after which microphotographs were obtained.
Fluoroquinolone concentrations in plasma were measured by reversedphase HPLC with fluorescence detection (P. Heizmann, unpublished results). The limit of quantification for all quinolones was 85 ng/ml. Assay limit for all tissues was 100 ng/g (/ml).
Pharmacokinetic Analyses
Pharmacokinetic parameters were determined by model-independent methods. The peak concentrations (cm"), predose concentrations (C""") and time-to-peak concentrations (T""0 were determined directly from the data points. Areas under the concentration-time curve were determined for one dosage interval (AUCo-24 I.) by the logarithmic trapezoidal rule.
RESULTS
Phase I: Developmental Toxicity of Fleroxacin
Maternal Toxicity
An increase in maternal toxicity (poor appetite, anorexia, emesis) was observed in animals treated with fleroxacin at 70 mg/kg-day on GD 20-34 and 35-49 (Table 1) . Six of the 10 dams in the early treatment period (GD 20-34) experienced poor appetite (i.e., decreased food consumption) for 2 to 8 days duration between GD 21 and 37 compared to one control animal with episodic anorexia (1-4 days duration; GD 20-34). Eight of 10 dams administered 70 mg/kgday in the late treatment period (GD 35-49) had poor appetite from 2 to 9 days during GD 36-50, compared to four dams in the low dose group (35 mg/kg-day; 2-4 days duration GD 29-60) and 0 controls. Emesis was observed for 1/10 (35 mg/kg-day; GD 20-34 treatment, 1 day), 1/10 (35 mg/kg-day; GD 35-49 treatment; 2 days duration), 6/10 (70 mg/kg-day, GD 20-34 treatment; 1-7 days duration), and 5/10 (70 mg/kg-day; GD 35-49 treatment; 3-10 days duration). One animal in the high dose group (GD 35-49) died on GD 50 after completing treatment and following frequent episodes of poor appetite, emesis, and weakness (see Table I ; Animal MCY 20910). Necropsy findings revealed severe pulmonary edema suggestive of drug inhalation.
Animals in all dose groups showed a decrease in body weight during treatment with a recovery of mean maternal weights (i.e., weight gain) following the treatment period (see Table 2 ). The mean percentage weight loss for treated animals (GD 20-34 and 35-49) during treatment was above the control range in the high dose group with no or minimal effects observed at 35 mg/kg-day.
Developmental Toxicity
An increase in embryolethality (GD 36-37) was observed for animals treated with 70 mg/kg-day on GD 20-34 only. Although biologically significant, the rate of embryolethality (4/10, 40%) for this treatment period was not statistically significant when compared to the 35 mg/kg-day (0/10, 0%) and the control loss rate (0/5, 0%). For treatment during GD 35-49, the results were as follows: 70 mg/kg-day (2/10, 20%), 35 mg/kg-day (1/10, 10%), and controls (0/5, 0%), with embryonic deaths between GD 42 and 49. Embryolethality during the later treatment period was not considered significantly different when compared to concurrent and historical control data for the colony (71/537; 13.2% from 1983 to 1989), although outcome could be suggestive of a dose response.
Sonographically, the following was observed:
For 70 mg/kg-day . On GD 25-32 an embryo with normative growth patterns (based on greatest length) was noted for Animal MCY 19345, although a decrease in embryonic heart rate (EHR) was observed on GD 29 (72-84 bpm; normal range = 132-176) and GD 32 (120-128 bpm). The embryo was determined nonviable on GD 36. Animals MCY 20817, 20824, and 21993 had similar findings (decreased EHRs on GD 28-29 and 32) with embryonic demise noted on GD 36 or 37.
For 70 mg/kg-day . Animal MCY 20918 was examined on GD 32, 39 (diminished EHR), and 44 (normal EHR); a nonviable embryo was detected on GD 49. Animal MCY 22940 had a normal, viable embryo on GD 33 which was nonviable on GD 42.
For 35 mg/kg-day . Animal MCY 23240 was noted with a normal embryo on GD 33 and 40; however, a diminished EHR (60-96 bpm) was noted on GD 45-47; a nonviable embryo was documented on GD 49.
All tissues were removed on the day of detection of nonviability and determined grossly normal.
No gross or skeletal malformations were observed in fetuses treated with fleroxacin (all doses and treatment groups) and examined on GD 100 ± 2. The normal range in skeletal variations were observed in all dose groups (see Table 3 ). Fetal body and organ weights were not significantly different between groups although fetuses exposed to 70 mg/kg-day during GD 20-34 fell within the lower range of normal (Tables 4 and 5 ). Placental evaluations did not reveal any significant findings.
No significant effects on serum P or CG concentrations were observed in any of the treatment groups. Urinary E,C levels for vehicle-controls and animals in the 35 mg/kg-day groups were similar; however, the mean values for both treatment periods in the 70 mg/kg-day group were reduced overall, particularly for those animals with nonviable embryos. When pooled by group, there was a trend toward decreasing concentrations with increasing dosages (i.e., control (GD 20-34 treatment) = 90.2 ± 24.6 ng/mg creatinine versus 70.8 ± 11.3 (35 mg/kg-day), 50.4 ± 7.4 (70 mg/kg-day, viable) and 18.2 ± 4.1 (nonviable)), although it was not statistically significant. A similar trend was observed during the GD 35-49 treatment period (control = 125.4 ± 30.6 versus 77.7 ± 13.4 (35 mg/kg-day), 68.5 ± 12.7 (70 mg/kg-day, viable), and 24.4 (nonviable)). Phase II: Comparative Pharmacokinetics Analysis of dosing suspensions indicated concentrations were within 6% of the anticipated range. Problems were encountered during the measurement of particle size including difficulties in preparation of a saturated solution of ciprofloxacin for use as the dispersion medium due to its high aqueous solubility. Similarly, norfloxacin and temafloxacin became flocculant in the carboxymethylcellulose, resulting in variable and nonreproducible particle size distributions in the different subsamples (top, middle, bottom). Consistent results were obtained for fleroxacin, which showed mean particle sizes of 2.0 gm (range of 0.6-6.0) for each sample. The microphotographs of the deflocculated systems indicated that all of the suspensions consisted of very fine primary particles, with a median particle size of -2-5 gm. It was, therefore, concluded that all of the test compounds were administered at the intended doses and in bioavailable forms.
Pharmacokinetics
The pharmacokinetic parameters for individual animals are presented in Table 6 . The mean plasma concentrationtime curves for all four fluoroquinolones are presented in 
Percentage weight change (% wt change) is relative to the pretreatment weight. % weight change = weight -Pretreatment Weight/Pre-treatment Weight x 100. GD, gestational day. Fig. 2a (Day 1) and Fig. 2b (Day 3) , with comparative data for fleroxacin in nongravid and gravid animals in Fig. 3 .
Ciprofloxacin. The first oral dose of ciprofloxacin was rapidly absorbed, and achieved peak concentrations between 1 and 3 hr postadministration. Despite the similar rates of absorption, a very pronounced interanimal variation was found in the Cmax, with values ranging from 1.13 to 8.94 µg/ml. In contrast, the Cmin values appeared to be less variable (<0.09-0.26 µg/ml), which may indicate that the interanimal variation was related to differences in the absorption of intact drug (oral bioavailability) rather than rates of elimination, which is similar to reports in the human (LeBel, 1988a) . The marked variation in C. also had a pronounced effect upon the AUCs for one dosage interval, resulting in approximately a 10-fold range in the values recorded (6.1-58.3 Aig • hr/m1). Little accumulation was noted, however, during repeat administration which is consistent with the comparatively low Cmin values observed. Although all of the individual parameters for each animal were higher on Day 3 than those on Day 1 of treatment, the individual increases in the Cmax and AUC values were all <30%.
Temafloxacin. The initial doses of temafloxacin were all rapidly absorbed (Tam), 2-3 hr), with little interanimal variation in the Cmax (6.92-10.23 µg/m1). Very consistent (and comparatively high) Calm values were also found in all three animals studied (1.12-1.16 µg/ml), resulting in higher and less variable AUC values (92.8 ± 5.4 Ag • hr/ml) when compared to those found for either ciprofloxacin (25.6 ± 28.5 ftg • hr/ml) or norfloxacin (7.5 ± 1.4 ktg • hr/ml). Approximately a twofold accumulation had also occurred by Day 3, with a mean AUC of 183.5 ± 52.8 Aig • hr/ml.
Norfloxacin. Compared to ciprofloxacin ( Tmax, 1-3 hr), norfloxacin was absorbed relatively slowly (Tmax, 3-7 hr), but the interanimal variation was much less pronounced for norfloxacin, both for Cmax and AUC values (ranges of 0.33-0.76 µg/ml and 5.9-8.5 Ag • hr/ml, respectively). Each individual animal showed measurable Cmin values on Day 1 of treatment (range, 0.12-0.18 µg/ml), and all of the individual Cmax and AUC values were higher on Day 3 than those on Day 1. An approximate twofold mean accumulation factor based on the AUC0_24 hr values (7.5 ± 1.4 versus 14.3 ± 7.4 ftg • hr/ml, for Days I and 3, respectively) was noted.
Fleroxacin. Unlike the other fluoroquinolones, the plasma concentration-time profiles for fleroxacin in nonpregnant animals did not show clearly defined maxima. Thus, the concentrations remained between 7.00 and 9.40 µg/ml from 2 to 7 hr postadministration for all animals studied. In addition, the Cmin values (4.32 ± 2.00 µg/ml) were approximately 50% of the C. (8.98 ± 0.57 µg/ml).
As a consequence, the AUC0_24 hr values for the first dose of fleroxacin (155.8 ± 27.7 ftg • hr/ml) were even higher than those for temafloxacin (92.8 ± 5.4 ktg • hr/ml). Despite the high Cmin values noted, fleroxacin did not accumulate mark- (n = 2) (n = 4) (n = 5) 9 ±0 9 ± 2 10 ±2 10 ± 0 (9) (7-11) (7-12) (10)
edly during repeat administration. Thus, although the AUC values on Day 3 (175.3 ± 25.1 lig • hr/ml) were all higher than those on Day 1, each of the individual values had increased by less than 25%. This finding may indicate that the "flat" profile for fleroxacin in the plasma of nongravid macaques is due to absorption rate-limited pharmacokinetics.
In the pregnant animals studied, peak concentrations after the first dose (10.47 ± 1.28 µg/ml) were marginally higher than those in the nonpregnant group (8.98 ± 0.57 µg/ml). Conversely, the pregnant animals showed lower ("nun values (3.27 ± 2.93 versus 4.32 ± 2.00 µg/ml) resulting in no overall differences in the AUC,_ values (156 4 24 hr ± 23.2 and 155.8 ± 27.7 tig • hr/ml, respectively). In contrast, both the mean C. and C""n values were slightly higher for the pregnant animals on Treatment Day 3 which resulted in slightly higher AUC values than those found in the nonpregnant group (197.1 ± 17.6 versus 175.3 ± 25.1 lig • hr/ ml), although the ranges of individual values overlapped (181.6-216.2 versus 146.8-193 .9 lig • hr/ml). The increase in AUC during repeat drug administration was <40% for each individual. HPLC analysis of the embryonic tissues indicate placental (9.31 ± 5.09 µg/g), chorionic fluid (6.00 ± 4.03 µg/ml), and embryo concentrations (7.68 ± 4.23 µg/g) comparable to those in the corresponding samples of maternal plasma (7.37 ± 1.40 µg/ml) ( Table 7) .
DISCUSSION
Studies with the fluoroquinolones have focused on identifying their potential for developmental toxicity/teratogenicity and assigning a no-observed-adverse-effect level (NOAEL). Developmental toxicity studies with the fluoroquinolones and multiple nonprimate species have been performed with no association between drug treatment and fetal malformations shown to date. Included are studies with norfloxacin and gravid mice, rats, and rabbits after oral administration of 550, 800, and 100 mg/kg-day, respectively (Cukierski et al., 1989) . However, fetal death and abortions were noted with maternotoxic doses. As described herein, administration of fleroxacin to cynomolgus monkeys (35 and 70 mg/kg-day) resulted in both maternal toxicity and embryolethality, although no teratogenicity was observed; a NOAEL of 35 mg/kg-day was established based on these data. Norfloxacin and temafloxacin have also been shown to induce similar maternal toxicity and embryolethality in the macaque at higher doses (150, 200/ 300 and 100 mg/kg-day, respectively) although exposure occurred over a longer period during gestation (GD 20-50) (Cukierski et al., 1989; Tarantal et al., 1990) compared to the split dosing regimen described for fleroxacin . The incidence of embryolethality was 30% (3/10; 150 mg/kg-day) and 69% (11/16, 200/300 mg/ kg-day) for norfloxacin and 50% (5/10; 100 mg/kg-day) for temafloxacin. Based on materno-and embryotoxicity, a NOAEL of 100 mg/kg was established for norfloxacin and 50 mg/kg for temafloxacin. In contrast to fleroxacin, temafloxacin, and norfloxacin, no increase in embryolethality was noted with oral doses of ---c.100 mg/kg-day ciprofloxacin which was also administered during GD 20-50 (Schluter, 1989) . These studies have attempted to elucidate the underlying causes of embryolethality which may be related to placental structure and function specifically in regards to hormone production. In macaques, hormonal maintenance of pregnancy is dependent upon CG rescue of the corpus luteum (CL) which enables continued P production until approximately GD 19-22 when the trophoblast assumes this role ("luteal-placental" shift) (Atkinson el al., 1975) . The role of placental-derived P in the cynomolgus macaque has been examined by surgical removal of the CL on GD 19 followed by administration of norfloxacin (100 mg/kg-day; daily GD 20-30) (Cukierski el al., 1992) . Results indicated ° One fetus with a decreased nasal angle and hypoplastic maxilla; one fetus with a slightly hypoplastic mandible. One fetus with a pair of 7th cervical ribs; one fetus with an accessory ossification site between 2 coccygeal vertebrae. `Two fetuses with a pair of 7th cervical ribs; one fetus with a pair of 7th cervical ribs and 11 thoracic vertebrae/rib pairs; one fetus with a single asymmetric coccygeal vertebrae.
d One fetus with a pair of 7th cervical ribs; one fetus with 11 thoracic vertebrae/rib pairs; one fetus with a single asymmetric coccygeal vertebra.
One fetus with a pair of 7th cervical ribs; one fetus with 13 thoracic ribs; fetus with hypoplastic mandible also had 13 thoracic ribs. fOne fetus with a pair of 7th cervical ribs and a small protuberance on superior aspect of 1st rib; three fetuses with 13 thoracic ribs. 8 One fetus with 13 thoracic ribs; one fetus with a single asymmetric coccygeal vertebra. a 70% (7/10) loss rate between GD 25 and 31 versus 0% (0/6) when compared to controls. A reduction of serum P, but not serum CG or E2 nor P and E urinary metabolites, was noted prior to embryonic loss. Since the urinary excretion levels were unchanged, these results suggested that the developmental toxic effects of norfloxacin may be related to an increased turnover of P rather than decreased P production. This may be due to an acceleration of P degradation with subsequent urinary excretion. Further studies with norfloxacin would be required in order to identify the specific mechanism for the embryotoxic effects, and whether the conceptus plays a role in this interaction (Cukierski et al., 1992) . No consistent pattern of serum hormonal effects have been observed for the other fluoroquinolones studied. Although a reduction in systemic P was noted prior to embryonic loss following exposure to temafloxacin, this was not a consistent finding and precluded the assumption that a toxic effect on the trophoblast had occurred (Tarantal et al., 1990) . In conjunction with a lack of materno-or embryotoxicity, there were no effects on P production in studies with ciprofloxacin (Schluter, 1989) . In the fleroxacin study, serum P and CG levels were similar to control values, although a reduction in urinary E,C in 5/6 animals with ultrasonographically confirmed nonviable embryos was noted.
Comparisons of the pharmacokinetics of fleroxacin, temafloxacin, and norfloxacin in nonpregnant macaques was studied following the first and third administrations of embryolethal doses to determine whether comparable AUCs and/or Cmax values could be obtained. Ciprofloxacin was included as a "nonembryolethal control" (Schluter, 1989) . Furthermore, since prior studies with norfloxacin suggested marginal differences in drug disposition between pregnant and nonpregnant animals (Cukierski et al., 1989) , a similar comparison with fleroxacin was pursued (treatment during GD 28-30). The rank order of systemic exposure, as determined from the AUC on the first day of treatment, was fleroxacin > temafloxacin > ciprofloxacin > norfloxacin which correlates reasonably well with the relative developmental toxicities (embryolethality) of these compounds. The rank order for embryolethality was fleroxacin > temafloxacin > norfloxacin > ciprofloxacin. The rank order of systemic exposure is also in reasonable agreement with observed or reported maternal toxicities. Typical adverse physical signs were poor appetite and emesis. A high incidence was found for fleroxacin at 70 mg/kg-day and for temafloxacin at 100 mg/kg-day (Tarantal et al., 1990) , whereas ciprofloxacin at 100 mg/kg-day showed only a low incidence of these adverse events (Schluter, 1989) . For norfloxacin the increase was significant only at very high dose levels (200-300 mg/kg-day) (Cukierski et al., 1989) . The given rank order of systemic exposure is unlikely to be changed, if only the exposure to free (unbound) drug is taken into account. In other species all of the compounds exhibit low protein binding. For example, the free fractions for norfloxacin, fleroxacin, and ciprofloxacin in human plasma are reported to be 86, 77, and 60-80%, respectively (LeBel, I 988b). Therefore, correcting for protein binding is unlikely to markedly influence the relative results.
Based on the Cana values and the AUC for one dosage interval, little accumulation of ciprofloxacin or fleroxacin occurred during the study period, whereas norfloxacin and temafloxacin resulted in an average exposure which increased approximately twofold. Following Day 3 administration, doses of fleroxacin and temafloxacin produced comparable values for both the Cm. (8.11 ± 0.36 µg/ml and 12.1 ± 2.56 Ag/ml) and AUC0_ 24 " (175.3 ± 25.1 versus 183.5 ± 52.8 Ag • hr/ml, respectively). In contrast, the nonembryolethal dose of ciprofloxacin showed much lower and more variable exposures (Cmax, 4.82 ± 5.78 µg/ml; AUC, 32.7 ± 21.2 Ag • hr/ml). This is consistent with results obtained in the rhesus monkey as noted above (Siefert et al., 1986) .
A major discrepancy in the anticipated exposures was seen with norfloxacin (Cmax , 1.74 ± 1.31 µg/m1; AUC, 14.3 ± 7.40 Ag • hr/ml). Thus, the dose of this fluoroquinolone apparently produced a level of exposure which was not only markedly lower than the other two "positive" test compounds (fleroxacin and temafloxacin) but which also appeared to be less than that for the "control" (ciprofloxacin). These results contrast markedly with prior reports for nonpregnant cynomolgus monkeys following the administration of a single oral dose of 50 mg/kg norfloxacin followed by 200 mg/kg 48 hr later (Cukierski et al., 1989) . Here, a more rapid absorption was observed ( Tmax , 2-3 hr), with much higher Cmax and AUC0_8 hr values both at 50 mg/kg (3.65-6.81 µg/ ml and 16.1-33.1 gg • hr/ml, respectively) and 200 mg/kg (8.74-15.60 pg/mI and 43.3-82.2 Ag • hr/ ml, respectively). In the study described herein it was confirmed that the correct doses were administered. Although it has been reported that particle size may have a strong influence on norfloxacin absorption (Gilfillan et al., 1984) , norfloxacin administered in the current protocol consisted of very fine primary particles and the observed flocculation was not expected to change its biopharmaceutical properties. Therefore, as particle size does not explain the differ-ences in norfloxacin levels, the discrepancies between the two studies may be explained by some procedural differences such as the use of ketamine prior to dosing (Cukierski et al., 1989) .
The observed differences in pharmacokinetic parameters in the macaque are consistent with those reported previously for the fluoroquinolones in humans. A comparison of the pharmacokinetics of norfloxacin (400 mg), ciprofloxacin (500 mg), and fleroxacin (400 mg) has shown that after a single oral dose all the quinolones were rapidly (but variably) absorbed with peak concentrations noted by 0.5-3 hr (Brouwers, 1987) . Ciprofloxacin was shown to be one of the most rapidly absorbed with time to maximum concentrations occurring -1.2 hr postadministration (2.3 µg/m1). Norfloxacin was absorbed more slowly and fleroxacin showed a more variable rate of absorption. While absolute bioavailability was nearly complete for fleroxacin (95-100%), reported values were more moderate and variable for norfloxacin (35-70%) and ciprofloxacin (45-84%). The half-lives and plasma protein binding (%) for norfloxacin, ciprofloxacin, and fleroxacin, respectively, were: 3-6 hr, 14%; 3-6 hr, 40%; and 8-12 hr, 23%. Other studies have indicated that human exposures (as determined by AUC0_,"f and Cmax values) are highest for fleroxacin and temafloxacin. After a single oral dose (400 mg) the AUCs were 52.1 and 28.4 µg • hr/ml and the Cmax values 4.6 and 3.3 µg/m1 for fleroxacin (Weidekamm and Portmann, 1989) and temafloxacin (Nye et al., 1989) , respectively. Compared to fleroxacin and temafloxacin, norfloxacin and ciprofloxacin yield lower plasma levels in humans. Following a single oral dose of 400 mg norfloxacin and 500 mg ciprofloxacin, the AUCs were 5.4 and 9.9 µg • hr/ml with Cmax values of 1.5 and 2.3 µg/ml, respectively (Wise et al., 1988) . Thus, the rank order of plasma concentrations in the human is fleroxacin > temafloxacin > ciprofloxacin > norfloxacin, which is comparable to the nonhuman primate data when correcting for the different doses incorporated. In the human, it has also been shown that the quinolones can readily traverse the placenta, with intravenous administration of 200 mg/kg ciprofloxacin (19 to 25 weeks gestation) resulting in serum concentrations of 0.01-0.28 µg/ml, whereas amniotic fluid levels ranged from 0.10 to 0.13 µg/ ml (Giamarellou et al., 1989) .
Overall, the results of these studies suggest a direct relationship between the exposures to the fluoroquinolones and the corresponding embryolethal doses in the cynomolgus monkey. In this regard, the plasma levels of temafloxacin and fleroxacin exceed the "threshold" for developmental toxicity, whereas ciprofloxacin levels did not reach this threshold. As discussed previously, this correlation does not appear to hold true for norfloxacin, presumably because of its different mechanism of action which may be related to increased P turnover, which was not evident for the other three fluoroquinolones. Fleroxacin levels in the embryo were comparable to maternal plasma levels, indicating unimpeded placental transport. In addition, there were no marked differences in pharmacokinetic parameters in pregnant and nonpregnant animals treated with fleroxacin; thus, the physiology of pregnancy does not appear to affect the pharmacokinetics of this fluoroquinolone. Further studies will be required to determine the developmental toxic threshold for ciprofloxacin and to determine the mechanism(s) by which the fluoroquinolones exert their embryotoxic effect.
